4-Tert-butyl-2,6-dimethyl-1,4-thiazinane 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: 4-Tert-butyl-2,6-dimethyl-1,4-thiazinane 1,1-dioxide
• 英文别名: 4-tert-butyl-2,6-dimethyl-1,4-thiazinane 1,1-dioxide
• 化学式: C₁₀H₂₁NO₂S
• 分子量: 219.35
• InChiKey: BXBWKQUGXDETQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• INHIBITORS OF C-FMS KINASE
  申请人：ILLIG Carl R.

  公开号：US20140148448A1

  公开（公告）日：2014-05-29

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及一种式子为I的化合物：其中Z，X，J，R2和W如规范中所述，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用式I化合物的方法，用于治疗自身免疫性疾病和有炎症成分的疾病；治疗来自卵巢癌，子宫癌，乳腺癌，结肠癌，胃癌，毛细胞白血病和非小细胞肺癌的转移；并用于治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经源性疼痛；以及骨质疏松症，帕吉特病和其他骨吸收介导的疾病，包括关节炎，假体失效，骨溶性肉瘤，骨髓瘤和肿瘤转移到骨骼。
• TRICYCLIC COMPOUNDS
  申请人：JACOBIO PHARMACEUTICALS CO., LTD.

  公开号：US20210179617A1

  公开（公告）日：2021-06-17

  Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
• US8722718B2
  申请人：——

  公开号：US8722718B2

  公开（公告）日：2014-05-13
• US8859602B2
  申请人：——

  公开号：US8859602B2

  公开（公告）日：2014-10-14
• US9221797B2
  申请人：——

  公开号：US9221797B2

  公开（公告）日：2015-12-29